Moderna Inc (MRNA) is developing different types of vaccines using the messenger RNA technology platform. Several promising programs are currently underway at the company.
The coronavirus vaccine, developed and approved by Moderna, has become its most famous mRNA vaccine. Nevertheless, this technology can be used to develop vaccines to prevent other deadly illnesses.
At present, 24 programs involving mRNA technology are developed by the company. In the past few weeks, Moderna has talked more about vaccines against seasonal flu, HIV and the Nipah virus.
Moderna Inc (MRNA) is currently testing a flu vaccine that prevents types of seasonal flu. Vaccines against coronavirus, respiratory syncytial virus, and human metapneumovirus will be part of the company’s current clinical trials, which will take place next year.
Two vaccines are included in Moderna’s HIV prevention program. The company and The Bill & Melinda Gates Foundation are developing one of these mRNAs, which is mRNA-1644. Simultaneously, the National Institutes of Health (NIH) may contribute to its evaluation of another mRNA, mRNA-1574. The clinical trials for both candidates will be conducted this year.
One other development is a vaccine against the Nipah virus. Several outbreaks of this disease have been observed in India, Bangladesh, Malaysia and Singapore and are listed by the World Health Organization as a potential epidemic threat. As a result, it is possible that if the vaccine is successful, it will be in demand in these densely populated areas.
In recent months, MRNA stock rose in response to progress in the development of vaccines against the coronavirus. A variety of vaccines based on advanced messenger RNA technology is the company’s key contributor to long-term success. The development of dozens of programs and several vaccines in advanced research stages could indicate Moderna’s continued growth.